Search Results
Dr. Goy on the Evolution of Treatment Selection in MCL
Dr. Goy Discusses Long-Term Follow-Up Results for Ibrutinib in MCL
CALQUENCE® (acalabrutinib) Perspectives: Dr Andre Goy, MD
Dr. Goy on Research Efforts With BTK Inhibitors in MCL
Dr. Goy on the Potential Utility of BTK Inhibitors as Maintenance in MCL
Dr. Goy Discusses Ibrutinib With Venetoclax in MCL
Dr. Smith on Frontline Treatment Options in MCL
Taking the Leap With Innovative Strategies in MCL
Dr. Martin on the Frontline Treatment Landscape of MCL
Zanubrutinib plus rituximab in first-line MCL therapy
Case Assessment: 68-Year-Old Patient With MCL
Dr. Kahl on the Potential of CAR T-Cell Therapy in MCL
